Karyopharm taps long­time Pfiz­er, Am­gen vet to steer the ship; With Mer­ck in the rearview mir­ror, Roger Perl­mut­ter stakes his claim to a CEO job — and it's a sur­pris­ing choice

Like many who work in bio­phar­ma, Richard Paul­son got start­ed in the field be­cause of a love of sci­ence.

Paul­son had just fin­ished busi­ness school and was look­ing to start a ca­reer that mar­ried his two pas­sions. While look­ing for jobs, he thought of his grand­moth­er who had strug­gled with Alzheimer’s dis­ease, re­call­ing how he saw first-hand what in­no­v­a­tive med­i­cines can do for pa­tients. Ul­ti­mate­ly, he start­ed his first job in the space as a sales rep at Glaxo Well­come, one of Glax­o­SmithK­line’s pre­de­ces­sors be­fore its merg­er with SmithK­line Beecham in 2000.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN